Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Operating Expenses: 2022-2024

  • Taysha Gene Therapies' Other Operating Expenses rose 685.39% to $4.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $42.3 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2024, which is 354.27% up from last year.
  • Taysha Gene Therapies' Other Operating Expenses amounted to $4.8 million in Q3 2024, which was up 977.51% from $449,000 recorded in Q4 2023.
  • In the past 5 years, Taysha Gene Therapies' Other Operating Expenses registered a high of $36.4 million during Q4 2022, and its lowest value of $449,000 during Q4 2023.
  • In the last 3 years, Taysha Gene Therapies' Other Operating Expenses had a median value of $2.7 million in 2023 and averaged $10.6 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Other Operating Expenses plummeted by 98.77% in 2023, and later soared by 685.39% in 2024.
  • Over the past 3 years, Taysha Gene Therapies' Other Operating Expenses (Quarterly) stood at $36.4 million in 2022, then slumped by 98.77% to $449,000 in 2023, then surged by 685.39% to $4.8 million in 2024.
  • Its last three reported values are $4.8 million in Q3 2024, $449,000 for Q4 2023, and $616,000 during Q3 2023.